๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Trial endpoints for drug approval in oncology: Chemoprevention

โœ Scribed by Julie Beitz

Book ID
117263389
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
91 KB
Volume
57
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Tissue autofluorescence as an intermedia
Tissue autofluorescence as an intermediate endpoint in cancer chemoprevention trials
โœ Stimson P. Schantz; Robert R. Alfano ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 583 KB

Intermediate endpoints which reflect responsiveness to chemopreventive agents are needed in clinical trials. A potential problem in the assessment of these endpoints is their requirement for invasive biopsies. Secondly, their expression within the aerodigestive tract is doubtfully uniform. Without c

Statistical validation of intermediate m
Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials
โœ Laurence S. Freedman; Arthur Schatzkin; Mark H. Schiffman ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 510 KB

Using an intermediate marker of precancer as an endpoint for evaluating agents that may prevent cancer involves a presumption that the modification of the marker will be accompanied by a modification of cancer incidence. This presumption can hold only if the marker is on or very closely linked to a